{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T14:10:39Z","timestamp":1783951839967,"version":"3.55.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010463","name":"Institute Curie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010463","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.clbc.2026.02.013","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T16:58:57Z","timestamp":1771865937000},"page":"37-43","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["SENOPAUSE: Evaluation of an ASCO-Derived Clinical Proxy for Axillary Risk Stratification in a Retrospective Cohort"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-0422-5382","authenticated-orcid":false,"given":"Michel Gabriel","family":"Cazenave","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Mahiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Elahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Maumy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9a","family":"Pauly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eug\u00e9nie","family":"Guillot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gr\u00e9goire","family":"Miailhe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Pouget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Benoit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathis","family":"Trotin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Bonneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.clbc.2026.02.013_bib0001","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.2017.11470","article-title":"Effect of axillary dissection vs. no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (alliance) randomized clinical trial","volume":"318","author":"Giuliano","year":"2017","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.clbc.2026.02.013_bib0002","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1001\/jama.2011.90","article-title":"Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial","volume":"305","author":"Giuliano","year":"2011","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.clbc.2026.02.013_bib0003","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S1470-2045(14)70460-7","article-title":"Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial","volume":"15","author":"Donker","year":"2014","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.clbc.2026.02.013_bib0004","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1200\/JCO.22.01565","article-title":"Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer: 10-year results of the randomized controlled EORTC 10981-22023 AMAROS trial","volume":"41","author":"Bartels","year":"2023","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clbc.2026.02.013_bib0005","doi-asserted-by":"crossref","first-page":"e251","DOI":"10.1016\/S1470-2045(13)70241-9","article-title":"Axillary versus sentinel-lymph-node dissection for micrometastatic breast cancer \u2013 authors\u2019 reply","volume":"14","author":"Galimberti","year":"2013","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1016\/j.clbc.2026.02.013_bib0006","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJMoa2313487","article-title":"Omitting axillary dissection in breast cancer with sentinel-node metastases","volume":"390","author":"De Boniface","year":"2024","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.clbc.2026.02.013_bib0007","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/jamaoncol.2023.3759","article-title":"Sentinel lymph node biopsy vs no axillary surgery in patients with small breast cancer and negative results on ultrasonography of axillary lymph nodes: the SOUND randomized clinical trial","volume":"9","author":"Gentilini","year":"2023","journal-title":"JAMA Oncol"},{"issue":"11","key":"10.1016\/j.clbc.2026.02.013_bib0008","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1056\/NEJMoa2412063","article-title":"Axillary surgery in breast cancer \u2014 primary results of the INSEMA trial","volume":"392","author":"Reimer","year":"2025","journal-title":"N Engl J Med"},{"issue":"4_Supplement","key":"10.1016\/j.clbc.2026.02.013_bib0009","doi-asserted-by":"crossref","first-page":"OT1-04-02","DOI":"10.1158\/1538-7445.SABCS21-OT1-04-02","article-title":"The NAUTILUS trial (no axillary surgical treatment in clinically lymph node negative patients after UltraSonography): a prospective multicenter randomized phase III trial (NCT04303715)","volume":"82","author":"Lee","year":"2022","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.clbc.2026.02.013_bib0010","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1186\/s12885-017-3443-x","article-title":"Clinically node negative breast cancer patients undergoing breast conserving therapy, sentinel lymph node procedure versus follow-up: a Dutch randomized controlled multicentre trial (BOOG 2013-08)","volume":"17","author":"Van Roozendaal","year":"2017","journal-title":"BMC Cancer"},{"issue":"9","key":"10.1016\/j.clbc.2026.02.013_bib0011","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-087700","article-title":"Omission of sentinel lymph node biopsy in patients with clinically axillary lymph node-negative early breast cancer (OMSLNB): protocol for a prospective, non-inferiority, single-arm, phase II clinical trial in China","volume":"14","author":"Li","year":"2024","journal-title":"BMJ Open"},{"issue":"14","key":"10.1016\/j.clbc.2026.02.013_bib0012","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1200\/JCO-25-00099","article-title":"Sentinel lymph node biopsy in early-stage breast cancer: ASCO guideline update","volume":"43","author":"Park","year":"2025","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clbc.2026.02.013_bib0013","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer","volume":"379","author":"Sparano","year":"2018","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.clbc.2026.02.013_bib0014","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","article-title":"21-Gene assay to inform chemotherapy benefit in node-positive breast cancer","volume":"385","author":"Kalinsky","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clbc.2026.02.013_bib0015","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1200\/JCO.2017.74.6586","article-title":"PAM50 risk of recurrence score predicts 10-year distant recurrence in a comprehensive Danish cohort of postmenopausal women allocated to 5 years of endocrine therapy for hormone receptor\u2013positive early breast cancer","volume":"36","author":"L\u00e6nkholm","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2026.02.013_bib0016","doi-asserted-by":"crossref","first-page":"270","DOI":"10.4274\/ejbh.galenos.2024.2024-5-11","article-title":"Applying the SOUND trial for omitting axillary surgery in patients with early breast cancer in Bahrain","volume":"26","author":"Abdulla","year":"2024","journal-title":"Eur J Breast Health"},{"issue":"10","key":"10.1016\/j.clbc.2026.02.013_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2025.110392","article-title":"Axillary surgery in early breast cancer: real-world analysis of the INSEMA-trial at three certified university breast cancer centers in Germany regarding the omission of sentinel lymph node biopsy","volume":"51","author":"Tauber","year":"2025","journal-title":"Eur J Surg Oncol"},{"issue":"11","key":"10.1016\/j.clbc.2026.02.013_bib0018","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35910","article-title":"Implications of omitting sentinel lymph node biopsy on adjuvant decision making for patients with small breast cancers","volume":"131","author":"Wanis","year":"2025","journal-title":"Cancer"},{"issue":"25","key":"10.1016\/j.clbc.2026.02.013_bib0019","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","article-title":"21-Gene assay to inform chemotherapy benefit in node-positive breast cancer","volume":"385","author":"Kalinsky","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2026.02.013_bib0020","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.breast.2021.11.018","article-title":"De-escalating axillary surgery in early-stage breast cancer","volume":"62","author":"Hersh","year":"2022","journal-title":"Breast"},{"issue":"13","key":"10.1016\/j.clbc.2026.02.013_bib0021","doi-asserted-by":"crossref","first-page":"8776","DOI":"10.1245\/s10434-024-16354-x","article-title":"Real-world implications of the SOUND trial","volume":"31","author":"Giannakou","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clbc.2026.02.013_bib0022","article-title":"Reconciling sentinel node omission with CDK4\/6 inhibitor eligibility in HR+\/HER2- early breast cancer: a real-world cohort analysis","author":"Kandzi","year":"2025","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.clbc.2026.02.013_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2025.104641","article-title":"Omission of sentinel lymph node biopsy in early stage luminal breast cancer: impact on adjuvant CDK4\/6 inhibitor recommendation and oncological outcomes","volume":"85","author":"Heidinger","year":"2026","journal-title":"Breast"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820926000261?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820926000261?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T23:16:26Z","timestamp":1776467786000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820926000261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1526820926000261"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2026.02.013","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SENOPAUSE: Evaluation of an ASCO-Derived Clinical Proxy for Axillary Risk Stratification in a Retrospective Cohort","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2026.02.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}